Pharma mid caps have survived well, Glenmark having grown OPM from 11% to 20%. Revenues have comfortably crossed the $200 mln threshold for the Quarter at INR 10 bln up more than 25% and more than INR 2 B in EBITDA 

Posted via email from The India Investment Post